50 and older, any sex, with Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Participants With a Hypotensive EpisodePrimary· Up to Month 12
Hypotension is defined as blood pressure \<100/40 mm Hg. Blood pressure was measured according to the American Heart Association guidelines with the subject in the sitting position and rested for 5 minutes. An appropriate cuff size (covering 60% of upper arm length and 80% of arm circumference) was used and correct cuff placement (1-2 inches above the brachial pulse on bare arm) was ensured.
Group
Value
95% CI
Candesartan
16
Placebo
4
Number of Participants With Symptoms of HypotensionPrimary· Up to Month 12
Participants were asked to report any symptoms of hypotension (dizziness, weakness, fatigue and lightheadedness). All participants were given a telephone number to reach physician 24-hours per day to report symptoms they experience. The number of participants reporting symptoms of hypotension is reported here.
Group
Value
95% CI
Candesartan
7
Placebo
10
Number of Participants With Hypotensive Episodes and SymptomsPrimary· Up to Month 12
The number of participants with reported episodes hypotension as well as symptoms of hypotension.
Group
Value
95% CI
Candesartan
4
Placebo
1
Number of Participants With Elevated Serum CreatininePrimary· Up to Month 12
The levels of creatinine were obtained from blood samples. Elevated serum creatinine is defined as levels \>2.5 milligram per deciliter (mg/dL). Elevated serum creatinine is indicative of decreased renal function.
Group
Value
95% CI
Candesartan
0
Placebo
0
Number of Participants With HyperkalemiaPrimary· Up to Month 12
The levels of potassium were obtained from blood samples. Hyperkalemia is defined as potassium levels \>5.9 milliequivalent per deciliter (meq/dL). Hyperkalemia is an indication of kidney dysfunction.
Group
Value
95% CI
Candesartan
0
Placebo
1
Number of Participants Discontinuing Study MedicationPrimary· Up to Month 12
The number of participants who discontinued the study medication is presented here.
Group
Value
95% CI
Candesartan
0
Placebo
1
Cerebrospinal Fluid (CSF) Total Tau LevelsSecondary· Baseline, Month 12
CSF total tau (t-tau) levels were analyzed from CSF samples obtained via lumbar puncture. Normal values for t-tau are \< 450 pg/ml. Elevated levels of t-tau indicate worsening disease.
Baseline Total Tau
Group
Value
95% CI
Candesartan
638.31
± 53.61
Placebo
529.04
± 53.50
Month 12 Total Tau
Group
Value
95% CI
Candesartan
571.96
± 52.89
Placebo
441.25
± 53.02
Cerebrospinal Fluid (CSF) of Tau Phosphorylated at Threonine 181 (p-tau181) LevelsSecondary· Baseline, Month 12
CSF levels of p-tau181 were analyzed from CSF samples obtained via lumbar puncture. P-tau181 is a biomarker that is elevated in persons with Alzheimer's disease. Higher values indicate worsening disease.
CSF Aβ42 levels were analyzed from CSF samples obtained via lumbar puncture. Aβ42 is a biomarker for Alzheimer's disease and lower values indicate worsening disease and an increased accumulation of amyloid in the brain.
CSF Aβ40 levels were analyzed from CSF samples obtained via lumbar puncture. Lower values indicate worsening disease and an increased brain accumulation of amyloid.
Arterial stiffness was assessed by Pulse Wave Velocity (PWV). PWV is calculated as PWV=distance (d)/time (t) and the unit of measure is reported as meters per second (m/s). Lower values indicate a preferable measurement of arterial stiffness.
Baseline
Group
Value
95% CI
Candesartan
7.81
7.12 – 8.51
Placebo
8.73
8.05 – 9.40
Month 12
Group
Value
95% CI
Candesartan
7.71
7.03 – 8.40
Placebo
8.14
7.47 – 8.81
Adverse events — posted to ClinicalTrials.gov
Time frame: Information on adverse events was collected for the duration of each participant's study enrollment, from the time that individuals gave consent to participate through their final study visit (up to 12 months)..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This study is intended to investigate the safety of candesartan, a blood pressure medication, in non-hypertensive individuals who have mild cognitive impairment (MCI) due to Alzheimer's disease and its effect on disease biomarkers.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT05321875 — Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)
· Phase 3
· recruiting
NCT05328635 — Post-traumatic Headache Multidisciplinary Study
· completed
NCT04606563 — Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on
· Phase 3
· terminated
NCT04430959 — Candesartan as an Adjunctive Treatment for Bipolar Depression
· EARLY_PHASE1
· withdrawn
Other recruiting trials for Mild Cognitive Impairment
Currently open trials in the same condition.
NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION
· NA
· recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
· Phase 1
· recruiting
NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen
· NA
· recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial
· NA
· recruiting
NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment
· NA
· recruiting
Other Emory University trials
Trials by the same sponsor.
NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study
· NA
· withdrawn
NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait
· NA
· not yet recruiting
NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose
· NA
· not yet recruiting
NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I
· Phase 2
· recruiting
NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emory University
Last refreshed: 1 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02646982.